中文摘要：

目的：观察华蟾素胶囊辅助卡培他滨口服治疗老年晚期胃癌的临床疗效。方法：将60例老年晚期胃癌患者随机分为治疗组和对照组各30例。治疗组给予卡培他滨联合华蟾素胶囊口服,至少完成2个及以上周期治疗,对照组给予卡培他滨口服治疗,比较分析临床近期疗效、生活质量改善率、疾病进展时间及总生存时间。结果：治疗组与对照组相比,近期疗效总有效率（46.7%vs 36.7%）和毒副反应无显著统计学差异（P〉0.05）,生活质量总改善率（76.7%vs 50.0%）、无进展生存期（6.2个月vs 4.9个月）和总生存期（11.2个月vs 9.6个月）具有显著统计学差异（P〈0.05）。结论：华蟾素胶囊辅助卡培他滨口服治疗老年晚期胃癌优于单药卡培他滨,安全有效。

英文摘要：

Objective ： To observe the effect of the combination of capecitabine and cinobufacin capsule on treating elderly advanced gastric cancer. Methods ： The treating group presented oral treatment of combine capecitabine with cinobufacin capsule, while the control group presented oral treatment of capecitabine. Statistical analysis was conformed in the short-term effect, quality of life （ QOL ）, improvement rate, time to progress/progress free survival （ TTP/PFS ） and overall survival （ OS ）. Results ： The two groups were similar in short-term effect （ overall response rate ） （ 46.7% vs 36.7% ） and toxic side-effect （ P〉0.05 ）. The treating group was significantly superior to the control group in QOL overall improvement rate （ 76.7%vs 50.0% ）, TTP （ PFS ） （ 6.2 vs 4.9 months ） and OS （ 11.2 vs 9.6 months ） （ P〈0.05 ）. Conclusion ： It＇s more effective to combine capecitabine with cinobufacin capsule than single cinobufacin capsule on treating elderly advanced gastric cancer.